Addition of dextran sulfate to blood cardioplegia attenuates reperfusion injury in a porcine model of cardiopulmonary bypass

被引:17
作者
Banz, Yara [1 ,2 ]
Rieben, Robert [1 ,2 ]
Zobrist, Claudia [3 ]
Meier, Pascal [4 ]
Shaw, Sidney [1 ]
Lanz, Jonas [1 ]
Carrel, Thierry [2 ]
Berdat, Pascal [2 ]
机构
[1] Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland
[2] Univ Hosp Bern, Dept Cardiovasc Surg, CH-3010 Bern, Switzerland
[3] Univ Hosp Bern, Dept Anesthesiol, CH-3010 Bern, Switzerland
[4] Univ Hosp Bern, Dept Cardiol, CH-3010 Bern, Switzerland
基金
瑞士国家科学基金会;
关键词
Ischemia; Reperfusion; Complement inhibition; Cytoprotection; Endothelium;
D O I
10.1016/j.ejcts.2008.05.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Contact of blood with artificial surfaces and air as well as ischemia/reperfusion injury to the heart and lungs mediate systemic and local inflammation during cardiopulmonary bypass (CPB). Activation of complement and coagulation cascades leads to and accompanies endothelial cell damage. Therefore, endothelial-targeted cytoprotection with the complement inhibitor and endothelial protectant dextran sulfate (DXS, MW 5000) may attenuate CBP-associated myocardial and pulmonary injury. Methods: Eighteen pigs (DXS, n = 10; phosphate buffered saline [PBS], n = 8) underwent standard cardiopulmonary bypass. After aortic cross-clamping, cardiac arrest was initiated with modified Buckberg blood cardioplegia (BCP), repeated after 30 and 60 min with BCP containing either DXS (300 mg/10 ml, equivalent to 5 mg/kg) or 10 ml of PBS. Following 30 min reperfusion, pigs were weaned from CPB. During 2 h of observation, cardiac function was monitored by echocardiography and invasive pressure measurements. Inflammatory and coagulation markers were assessed regularly. Animals were then sacrificed and heart and lungs analyzed. Results: DXS significantly reduced CK-MB levels (43.4 +/- 14.8 ng/ml PBS, 35.9 +/- 11.1 ng/ml DXS, p = 0.042) and significantly diminished cytokine release: TNF alpha (1507.6 +/- 269.2 pg/ml PBS, 222.1 +/- 125.6 pg/ml DXS, p = 0.0071), IL1 beta (1081.8 +/- 203.0 pg/ml PBS, 110.7 +/- 79.4 pg/ml DXS, p = 0.0071), IL-6 (173.0 +/- 91.5 pg/ml PBS, 40.8 +/- 19.4 pg/mt DXS, p = 0.002) and IL-8 (304.6 +/- 81.3 pg/ml PBS, 25.4 +/- 14.2 pg/ml DXS, p = 0.0071). Tissue endothelin-1 levels were significantly reduced (6.29 +/- 1.90 pg/100 mg PBS, 3.55 +/- 1.15 pg/100 mg DXS p = 0.030) as well as thrombin-anti-thrombin formation (20.7 +/- 1.0 mu g/ml PBS, 12.8 +/- 4.1 mu g/ml DXS, p = 0.043). Also DXS reduced cardiac and pulmonary complement deposition, neutrophil infiltration, hemorrhage and pulmonary edema (measured as lung water content, 81 +/- 3% vs 78 3%, p = 0.047), indicative of attenuated myocardial and pulmonary CPB-injury. Diastolic left ventricular function (measured as dp/dt(min)), pulmonary artery pressure (21 +/- 3 mmHg PBS, 19 +/- 3 mmHg DXS, p = 0.002) and right ventricular pressure (21 +/- 1 mmHg PBS, 19 +/- 3 mmHg DXS p = 0.021) were significantly improved with the use of DXS. Conclusions: Addition of DXS to the BCP solution ameliorates post-CPB injury and to a certain extent improves cardiopulmonary function. Endothelial protection in addition to myocyte protection may improve post-CPB outcome and recovery. (c) 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:653 / 660
页数:8
相关论文
共 25 条
[1]   Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury [J].
Banz, Y ;
Hess, OM ;
Robson, SC ;
Mettler, D ;
Meier, P ;
Haeberli, A ;
Csizmadia, E ;
Korchagina, EY ;
Bovin, NV ;
Rieben, R .
EUROPEAN HEART JOURNAL, 2005, 26 (21) :2334-2343
[2]   Elimination of proinflammatory cytokines in pediatric cardiac surgery: Analysis of ultrafiltration method and filter type [J].
Berdat, PA ;
Eichenberger, E ;
Ebell, J ;
Pfammatter, JP ;
Pavlovic, M ;
Zobrist, C ;
Gygax, E ;
Nydegger, U ;
Carrel, T .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 127 (06) :1688-1696
[3]  
Bruins P, 1997, CIRCULATION, V96, P3542
[4]   Methylprednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation [J].
Chaney, MA ;
Durazo-Arvizu, RA ;
Nikolov, MP ;
Blakeman, BP ;
Bakhos, M .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 121 (03) :561-569
[5]   Intraoperative interventions - American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery [J].
Creswell, LL ;
Alexander, JC ;
Ferguson, TK ;
Lisbon, A ;
Fleisher, LA .
CHEST, 2005, 128 (02) :28S-35S
[6]  
DAHA MR, 1981, IMMUNOLOGY, V43, P513
[7]   EVIDENCE OF CARDIAC INFLAMMATION AFTER OPEN-HEART OPERATIONS [J].
ELGEBALY, SA ;
HOUSER, SL ;
ELKERM, AFE ;
DOYLE, K ;
GILLIES, C ;
DALECKI, K .
ANNALS OF THORACIC SURGERY, 1994, 57 (02) :391-396
[8]   Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass [J].
Fitch, JCK ;
Rollins, S ;
Matis, L ;
Alford, B ;
Aranki, S ;
Collard, CD ;
Dewar, M ;
Elefteriades, J ;
Hines, R ;
Kopf, G ;
Kraker, P ;
Li, L ;
O'Hara, R ;
Rinder, C ;
Rinder, H ;
Shaw, R ;
Smith, B ;
Stahl, G ;
Shernan, SK .
CIRCULATION, 1999, 100 (25) :2499-2506
[9]   CONTROLLED TRIAL OF COMBINED UROKINASE AND DEXTRAN SULFATE THERAPY IN PATIENTS WITH ACUTE CEREBRAL INFARCTION [J].
FUJISHIMA, M ;
OMAE, T ;
TANAKA, K ;
IINO, K ;
MATSUO, O ;
MIHARA, H .
ANGIOLOGY, 1986, 37 (07) :487-498
[10]   The-174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? [J].
Gaudino, M ;
Andreotti, F ;
Zamparelli, R ;
Di Castelnuovo, A ;
Nasso, G ;
Burzotta, F ;
Iacoviello, L ;
Donati, MB ;
Schiavello, R ;
Maseri, A ;
Possati, G .
CIRCULATION, 2003, 108 (10) :195-199